SWX:NOVNPharmaceuticals
Novartis Adds Rare Disease Depth And Cardiovascular Optionality For Investors
Novartis received FDA approval for Cosentyx to treat pediatric hidradenitis suppurativa, expanding options for adolescent patients with this chronic skin disease.
The approval makes Cosentyx the first IL-17A inhibitor cleared for this pediatric indication in the United States.
Novartis also signed a licensing agreement with Unnatural Products to develop macrocyclic peptide therapeutics for cardiovascular diseases.
The deal targets previously hard-to-address cardiovascular drug targets and...